GENE ONLINE|News &
Opinion
Blog

2019-03-05| Technology

Novo Nordisk Pharma Ltd. Partners with Health2Sync in Japan, Bringing Digital Diabetes Management to Healthcare Providers and Patients

by GeneOnline
Share To

Tokyo, Japan and Taipei, Taiwan, March 5th, 2019 – Health2Sync and Novo Nordisk Pharma Ltd. are partnering in Japan to support digital diabetes management and facilitate communication between diabetics and healthcare providers. Last December, the two companies agreed to support the localization and promotion of the “SyncHealth” App (known as Health2Sync outside of Japan) and web platform for patient management.

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given Novo Nordisk experience and capabilities that also enable it to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Novo Nordisk recognises the need for solutions beyond medicines. Therefore, Novo Nordisk and Health2Sync are partnering to promote digital health strategy by providing support tools, services and programs that can contribute to improving outcomes of patients.

Health2Sync was founded in 2013, which provides a comprehensive health management platform for people with diabetes. It combines mobile, cloud, and data analytics, enabling patients to obtain personalized care, and allowing care providers and family members to care for patients remotely.

People living with diabetes require constant vigilance in making the right lifestyle choices and remembering to take their medications. Health2Sync bridges the lengthy gap between doctor visits by enabling frequent digital touch points between patients and healthcare providers. Through its behavioral AI engine, the App can provide hints and nudges concerning meals, exercise, and blood glucose management, delivered in a compelling and friendly way that encourages users to stay adherent to their treatment plans.

As part of the partnership, Novo Nordisk Pharma Ltd. will support the distribution and adoption of the SyncHealth app and healthcare provider platform in Japan. In the future, Novo Nordisk Pharma Ltd. aims to wirelessly connect its insulin delivery devices, enabling auto data recording of self-injected insulin. The SyncHealth App and the SyncHealth Platform are products developed for people living with diabetes, and H2 is solely responsible and liable for the products’ usage. Also, when providing such products or services, H2 directly acquires user data (including personal information) after obtaining user’s consent, and H2 is fully responsible and liable for preserving and processing such data.

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
EMA Upholds Recommendation For Withdrawing Marketing Authorization for Amfepramone Obesity Medicines
2022-10-28
M&A
Novo Nordisk Finally Finalizes their Billion Dollar Acquisition of Forma Therapeutics
2022-10-14
Novo Nordisk Places $700 Million Bet on Ventus’ NLRP3 Inhibitor Program
2022-09-30
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!